Monitoring the expression of genes involved in B-cell development using RNA flowcytometry in relation to Acute Lymphoblastic Leukemia
Year: 2024
Type: dissertation
Abstract: Despite being the most common type of pediatric cancer, the causes of Acute Lymphoblastic Leukemia (ALL) are not yet fully elucidated. ALL blasts are typically committed to B-cell development (B-ALL), the transformation process largely being driven by mutations in genes controlling B-cell fate. Genetic background is of importance as recent GWAS studies have pinpointed loci in genes such as IKZF1 and ARID5B harboring single nucleotide polymorphisms (SNPs) associated with increased predisposition to B-ALL. While the IKAROS transcription factor encoded by the IKZF1 gene is a well-known regulator of B-lymphoid differentiation, less is known about the role of the ARID5B gene in the B-cell development. The purpose of the current study was to explore the relationship between IKAROS and ARID5B expression in lymphocytes and B-ALL using a novel technique, the PrimeFlow RNA assay from Invitrogen, which is based on branched DNA (bDNA) technology that allows simultaneous analysis of RNA transcripts and proteins on a single cell level using flow cytometry. Our results demonstrate that inhibitory substances in peripheral blood largely hinder conduction of successful RNA expression analysis with the PrimeFlow method while cell line RNAs are easily targeted. The potential of the method to verify ARID5B RNA expression was confirmed in HEK293T cell lines with CRISPR edited control of ARID5B expression. The PrimeFlow method was used to evaluate the effect of pharmaceutical drugs including bexarotene, CK2-inhibitor and lenalidomide that were previously reported to specifically target the IKAROS protein. The results show that bexarotene and CK2-inhibitor did not promote restoration of IKAROS as expected, while the degrading effect of lenalidomide was confirmed in the REH and Nalm6 Pre-B cell lines. A twofold reduction of IKAROS protein staining was seen with lenalidomide administration, accompanied by dramatic increase of IKZF1 RNA which interestingly, was restricted to the S and G2 phases of the cell cycle. Furthermore, the degradation of IKAROS did not consistently alter ARID5B RNA concentrations, in contrast to previous reports implicating IKAROS as an upstream regulator of ARID5B. The Primeflow method is time consuming, involves multiple steps, requires accurate pre-analytical optimization and hands-on technical training. However, this method can be a powerful tool for evaluating the dynamic relationship between protein and RNA expression in efficiently controlled experiments using cell line models.
Source: Skemman
Author: Valeria De Souza Coelho
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7112283102
